Pamiparib

Pamiparib is an orally available, selective inhibitor of poly (ADP-ribose) polymerase (PARP). It primarily targets PARP1 and PARP2 enzymes, which play crucial roles in DNA repair. By inhibiting these enzymes, pamiparib disrupts DNA repair mechanisms in cancer cells, particularly those with homologous recombination deficiency (HRD), such as those with BRCA1/2 mutations. This disruption leads to an accumulation of DNA damage and ultimately, cancer cell death.

Pamiparib is being investigated as a potential treatment for various cancers, including ovarian cancer, small cell lung cancer (SCLC), and other solid tumors. Clinical trials are ongoing to evaluate its efficacy and safety, both as a monotherapy and in combination with other anti-cancer agents.

The use of pamiparib is associated with potential side effects, which may include hematological toxicities (e.g., anemia, thrombocytopenia, neutropenia), fatigue, nausea, and other gastrointestinal disturbances. The severity and incidence of these side effects can vary depending on the individual patient and the treatment regimen. Regular monitoring of blood counts and other relevant parameters is typically recommended during pamiparib treatment.